{
    "organizations": [],
    "uuid": "6626b511f5b4b15b021ffe98e53217af33366d68",
    "author": "",
    "url": "https://www.reuters.com/article/brief-first-patient-treated-in-mapi-phar/brief-first-patient-treated-in-mapi-pharmas-phase-ii-clinical-trialof-ga-depot-idUSASB0C2Z4",
    "ord_in_thread": 0,
    "title": "BRIEF-First Patient Treated In Mapi Pharma's Phase II Clinical Trial Of GA Depot",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 30, 2018 / 1:19 PM / in 13 minutes BRIEF-First Patient Treated In Mapi Pharma's Phase II Clinical Trial Of GA Depot Reuters Staff 1 Min Read \nJan 30 (Reuters) - Mapi Pharma Ltd: \n* FIRST PATIENT TREATED IN MAPI PHARMAâ€˜S PHASE II CLINICAL TRIAL OF GA DEPOT FOR PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) Source text for Eikon: Further company coverage:",
    "published": "2018-01-30T15:19:00.000+02:00",
    "crawled": "2018-01-30T15:45:05.066+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "patient",
        "treated",
        "mapi",
        "pharma",
        "phase",
        "ii",
        "clinical",
        "trial",
        "ga",
        "depot",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "mapi",
        "pharma",
        "ltd",
        "first",
        "patient",
        "treated",
        "mapi",
        "pharma",
        "phase",
        "ii",
        "clinical",
        "trial",
        "ga",
        "depot",
        "primary",
        "progressive",
        "multiple",
        "sclerosis",
        "ppms",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}